Blue Water Vaccines changed its corporate name to Blue Water Biotech, following its recent acquisition of ENTADFI, an FDA-approved treatment for benign prostatic hyperplasia, which has begun Blue Water’s transition into a commercial-stage biotechnology company.
Blue Water’s common stock will continue to trade on NASDAQ under the ticker symbol, BWV.
“Over the last few months, we have carefully developed a strong and experienced management team to lead us as we navigate this transition, and we are confident that the future of Blue Water and this product are very bright,” Joseph Hernandez, chairman and CEO of Blue Water, said in a statement.
In addition to ENTADFI, Blue Water is developing multiple vaccines to prevent infectious diseases, including lead vaccine, BWV-201, a Streptococcus pneumoniae vaccine targeting acute otitis media and pneumococcal pneumonia.
Blue Water also is developing a universal influenza vaccine, as well as vaccines for Marburg virus disease, and an orally-delivered chlamydia vaccine.
